HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors

Joyce A. O’Shaughnessy, MD, and Matthew P. Goetz, MD, elucidate the differences between the 3 available CDK4/6 inhibitors in hormone receptor–positive breast cancer, palbociclib, ribociclib, and abemaciclib.